AKT1 and hepatocellular carcinoma: In summary, we developed a model of HGF/Met signaling pathway to Akt and ERK with details of interactions with α5β1 integrin, which was calibrated and validated with a consistent set of experimental data from hepatocytes and human HCC cell lines that allowed us to better understand the mechanism of action of AXT050 and other HGF pathway-targeting therapeutics.